Gland Pharma Ltd. (IN:GLAND)
:GLAND
Want to see IN:GLAND full AI Analyst Report?
Total Valuation
Gland Pharma Ltd. has a market cap or net worth of ₹365.86B. The enterprise value is ₹335.30B.
Market Cap₹365.86B
Enterprise Value₹335.30B
Share Statistics
Gland Pharma Ltd. has 164,756,420 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding164,756,420
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Gland Pharma Ltd.’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 7.63%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)7.63%
Return on Capital Employed (ROCE)0.11
Revenue Per Employee15.25M
Profits Per Employee2.44M
Employee Count4,217
Asset Turnover0.51
Inventory Turnover2.58
Valuation Ratios
The current PE Ratio of Gland Pharma Ltd. is 27.2. Gland Pharma Ltd.’s PEG ratio is 0.58.
PE Ratio27.2
PS Ratio4.35
PB Ratio2.70
Price to Fair Value2.70
Price to FCF37.74
Price to Operating Cash Flow61.69
PEG Ratio0.58
Income Statement
In the last 12 months, Gland Pharma Ltd. had revenue of 64.31B and earned 10.27B in profits. Earnings per share was 62.35.
Revenue64.31B
Gross Profit19.32B
Operating Income12.06B
Pretax Income14.65B
Net Income10.27B
EBITDA16.30B
Earnings Per Share (EPS)62.35
Cash Flow
In the last 12 months, operating cash flow was 5.93B and capital expenditures -1.94B, giving a free cash flow of 3.99B billion.
Operating Cash Flow5.93B
Free Cash Flow3.99B
Free Cash Flow per Share24.24
Dividends & Yields
Gland Pharma Ltd. pays an annual dividend of ₹18, resulting in a dividend yield of 1.07%
Dividend Per Share₹18
Dividend Yield1.07%
Payout Ratio37.52%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.65
52-Week Price Change42.53%
50-Day Moving Average1.77K
200-Day Moving Average1.83K
Relative Strength Index (RSI)74.58
Average Volume (3m)9.08K
Important Dates
Gland Pharma Ltd. upcoming earnings date is Aug 11, 2026, TBA (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Gland Pharma Ltd. as a current ratio of 4.68, with Debt / Equity ratio of 2.74%
Current Ratio4.68
Quick Ratio3.60
Debt to Market Cap<0.01
Net Debt to EBITDA-1.89
Interest Coverage Ratio36.24
Taxes
In the past 12 months, Gland Pharma Ltd. has paid 4.37B in taxes.
Income Tax4.37B
Effective Tax Rate0.30
Enterprise Valuation
Gland Pharma Ltd. EV to EBITDA ratio is 15.26, with an EV/FCF ratio of 33.58.
EV to Sales3.87
EV to EBITDA15.26
EV to Free Cash Flow33.58
EV to Operating Cash Flow20.20
Balance Sheet
Gland Pharma Ltd. has ₹27.04B in cash and marketable securities with ₹3.02B in debt, giving a net cash position of ₹24.02B billion.
Cash & Marketable Securities₹27.04B
Total Debt₹3.02B
Net Cash₹24.02B
Net Cash Per Share₹145.77
Tangible Book Value Per Share₹604.22
Margins
Gross margin is 30.05%, with operating margin of 18.75%, and net profit margin of 15.98%.
Gross Margin30.05%
Operating Margin18.75%
Pretax Margin22.77%
Net Profit Margin15.98%
EBITDA Margin25.34%
EBIT Margin18.75%
Analyst Forecast
The average price target for Gland Pharma Ltd. is ₹2,080.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target₹2,080.00
Price Target Upside21.36% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast14.50%
EPS Growth Forecast47.08%